Checkpoint Therapeutics, Inc. (CKPT) News
Filter CKPT News Items
CKPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CKPT News Highlights
- For CKPT, its 30 day story count is now at 3.
- Over the past 10 days, the trend for CKPT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest CKPT News From Around the Web
Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Stock Plunged -23.15% So Far In 2022, What Analysts Expect Next?In last trading session, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) saw 0.87 million shares changing hands with its beta currently measuring 1.69. Companys recent per share price level of $2.39 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $185.56M. That closing price of CKPTs stock is Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Stock Plunged -23.15% So Far In 2022, What Analysts Expect Next? Read More » |
2 Biotech Stocks That Could Be 10-Baggers in 2022These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher. |
Checkpoint Therapeutics'' Cosibelimab Posts 47.4% ORR In Skin Cancer PatientsCheckpoint Therapeutics Inc (NASDAQ: CKPT ) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4%. The median duration of response (DOR) had Full story available on Benzinga.com |
Checkpoint reports positive results from registration trial of cosibelimab in skin cancerCheckpoint Therapeutics (CKPT) announces positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, |
Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology ConferenceWALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Justin Walsh, Equity Research Analyst (Biotechnology), at the B. Riley Securities’ Virtual Oncology Conference, taking place on Thursday, January 27, 2022, at 11:00 a.m. EST. Checkpoint management will als |
Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer PatientsCheckpoint Therapeutics Inc (NASDAQ: CKPT) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4%. The median duration of response (DOR) had not yet been reached at the data cut-off point (76% of responses are ongoin |
Why Checkpoint Therapeutics Stock Is Heating Up TodayBased on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way. |
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell CarcinomaStudy met primary endpoint with 47.4% objective response rateSafety and tolerability profile consistent with previously reported dataPlanned BLA submission on track for later this yearConference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topline results from its registration-enabl |
Will Checkpoint Therapeutics Inc. (NASDAQ: CKPT) Stock Boom Or Bust From Here?During the last session, Checkpoint Therapeutics Inc. (NASDAQ:CKPT)s traded shares were 0.96 million, with the beta value of the company hitting 1.62. At the end of the trading day, the stocks price was $2.94, reflecting an intraday gain of 2.80% or $0.08. The 52-week high for the CKPT share is $5.38, that puts it down Will Checkpoint Therapeutics Inc. (NASDAQ: CKPT) Stock Boom Or Bust From Here? Read More » |
An Analysis Of Checkpoint Therapeutics Inc. (NASDAQ: CKPT), And Its Business ForecastIn the last trading session, 1.33 million shares of the Checkpoint Therapeutics Inc. (NASDAQ:CKPT) were traded, and its beta was 1.62. Most recently the companys share price was $2.80, and it changed around -$0.17 or -5.72% from the last close, which brings the market valuation of the company to $236.94M. CKPT currently trades at a An Analysis Of Checkpoint Therapeutics Inc. (NASDAQ: CKPT), And Its Business Forecast Read More » |